By Maria Armental
Zosano Pharma Corp. on Friday warned it would need a substantial cash infusion to remain in business, sending shares down 17% to $1.58 in after-hours trading.
The clinical-stage biopharmaceutical company, which had said it was suspending its lead product candidate program and laying off employees, reported a first-quarter net loss of $33.4 million, or $7.86 a share, as it booked an impairment loss of $25.9 million for the three months ended March 31. That included a write-down of $24.8 million of property and equipment and $1.1 million of right-of-use assets and it was largely related to company's suspended M207 program.
Zosano said that as of May 11 it had about $9.9 million in cash and that it would need "substantial additional funding to fund its operations and will not be able to continue as a going concern if it is unable to raise additional funds."
Separately, it said that it would reduce the size of its board, following the resignation of Joseph "Jay" P. Hagan, the chairman of the audit committee.
Mr. Hagan's resignation, the company said, isn't based on any disagreement.
Write to Maria Armental at maria.armental@wsj.com
$(END)$ Dow Jones Newswires
May 13, 2022 16:25 ET (20:25 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。